Wednesday, 30 July 2014

According to a new market report published by Transparency Market Research "Electrophysiology Devices Market (ECG, EEG, Holter Monitoring Systems, Diagnostic Electrophysiology Catheters, Pacemaker, Imaging and 3D Mapping Systems) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global electrophysiology devices market was valued at USD 2,500.0 million in 2012 and is estimated to reach a market worth USD 5,496.6 million in 2019 at a CAGR of 12.1% from 2013 to 2019.

Electrophysiology is the study of electrical properties of biological cells. Electrophysiology devices are used for diagnosing and treating abnormal electrical activities in the heart, brain and eyes. The market for electrophysiology devices is expected to grow impressively with the rise in prevalence of cardiac diseases, increasing healthcare expenditure and technological advancements. With the rising adoption of ablation techniques especially for the treatment of atrial fibrillation, the electrophysiology market is expected to grow rapidly. On the other hand, strict regulatory approvals, high costs associated with devices coupled with availability of alternate medications are some of the challenges faced by the electrophysiology devices market.

The market for electrophysiology devices primarily comprises electrophysiology monitoring devices and treatment devices. Monitoring devices used in electrophysiology include electrocardiograph, electroencephalograph, electromyography, electroretinograph, diagnostic catheters and others. These devices enable physicians to understand the nature and origin of abnormal electrical impulses generating in the single ion channel cells to organs like the heart, brain and eyes. The outcomes help physicians in proper decision-making regarding treatment options, whether a patient needs medication or should opt for cardiac arrhythmic device implantation or catheter assisted ablation. Catheter ablation is a relatively new technique compared to implantation of cardiac arrhythmias devices. Due to its minimal invasive nature and efficacy, catheter ablation is the most commonly used treatment option for atrial fibrillation and other cardiac arrhythmias.

North America constitutes the largest market for electrophysiology devices. Factors such as presence of large number of well-equipped healthcare facilities, rising prevalence of diseases (cardiac arrhythmias, ophthalmic disorders and epilepsy) that require electrophysiology monitoring, and established healthcare policies providing access to better healthcare facilities are driving the market in the region. The fact that majority of the key players in the electrophysiology market including Medtronic Inc., St. Jude Medical and Boston Scientific are based in the U.S. and consider this as their primary revenue generating market, also acts as a driver. In addition, economic liberalization in emerging nations such as India, China, Brazil, Mexico, South Africa and Russia is attracting manufacturers to shift their focus to these regions. The above mentioned shift in focus will help Asia-Pacific and Rest of the World (RoW) to increase their market share during the forecast period. Asia-Pacific has been anticipated to emerge as the fastest growing geography during the forecast period from 2013 to 2019.

Some of the key market players of the global electrophysiology devices market include St. Jude Medical, Boston Scientific, Medtronic, Inc., Philips Healthcare and others. To gain a proficient market share, manufacturers are coming up with innovative products. The global electrophysiology devices market includes companies such as Abbott Laboratories, Boston Scientific, Medtronic, Inc., GE Healthcare, Philips Healthcare, St. Jude Medical among others.

A growing prevalence of target disease segments such as prostate cancer, diabetic retinopathy, chronic pain causing diseases, cardiovascular diseases, colorectal cancer, a rising global prevalence of unwanted pregnancies and a rapidly aging global population are some of the most impact rendering drivers for the global implantable drug delivery devices market. Some of the other drivers for the market include government and NGO initiatives undertaken to promote contraceptive drug delivery implants, rising number of interventional cardiologists and the rising demand for minimally invasive surgeries. Introduction of biodegradable implantable drug delivery technologies and new products such as MicroChips catering to disease segments such as osteoporosis will serve the market as future growth opportunities.

The market for implantable drug delivery devices in cardiovascular applications held majority of the market share in 2011 and owing to the introduction of bio-absorbable stents expected in 2014, its market share is likely to witness further increase by 2018. The biodegradable drug delivery implant technology will grow at a faster CAGR in comparison to the non-biodegradable drug delivery implant technology due to the fact that they do not involve re-surgeries for device removal and eliminates side effects induced by the prolonged presence of the device in the body.

The North American implantable drug delivery devices market held majority of the market share in 2011. However, its market share is expected to drop by 2018 owing to the accelerated market growth in the Asian regions induced by the economic development of emerging nations with high unmet medical needs such as India and China.

Merck held a majority of the market share in the global contraceptive drug delivery implants market due to the high adoption rate of its implants namely NuvaRing, Implanon and Implanon Nxt. Merck is closely followed by Bayer HealthCare with its widely used hormonal IUD Mirena and the launch of a new hormonal IUD Skyla in the U.S. and Jaydess in Europe in 2013.

According to a new market report published by Transparency Market Research "Medical Imaging Equipment Market (X-ray, Ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Nuclear Imaging Equipment) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," in 2012, the global medical imaging equipment market was valued at USD 24.39 billion and is expected to grow at a CAGR of 5.4% during the forecast period of 2013 to 2019 to reach a market value of USD 35.35 billion by 2019.

Medical imaging equipment helps in diagnosing various complex diseases such as chromosomal abnormalities, atherosclerosis and Parkinson's disease. This equipment utilizes energy waves to produce 2-D and 3-D images of human organs. With rise in incidences of various diseases such as cardiovascular diseases (CVD), brain disorders, oral conditions such as gingivitis, and lung disorders, the market is expected to grow at a CAGR of 5.4% during the forecast period of 2013 to 2019.

According to an estimate of the World Health Organization (WHO), around 8.7 million people suffered from tuberculosis (TB) in 2011 worldwide and around 23.3 million people will die due to CVDs. Growth of this market will also be supported by the increasing geriatric population worldwide because elderly people are highly susceptible to various diseases such as osteoporosis, stroke and CVDs. Equipment such as nuclear imaging devices and computed tomography (CT) scanners help in diagnosing these diseases precisely within a short span of time. Moreover, introduction of various technologically advanced products such as handheld X-ray machines and upright MRI scanners will also augment growth of this market. This is attributed mainly to increase in their utilization in various medical institutes, such as hospitals and diagnostic labs, since they reduce installation cost and also provide convenience of use.

Likewise, support from various private and government bodies will also trigger the growth of this market. For instance, the U.S. government introduced the Medicare Benefit Schedule (MBS) in 2011 which provides rebates for different categories of items including medical devices. However, imposition of excise tax on the sale of medical devices by the manufacturers and low adoption rate in patients for conventional MRI and CT scanners will hamper the growth of this market. According to the Patient Protection and Affordable Care Act (PPACA) of the U.S., medical device manufacturers are expected to pay an additional medical device excise tax (MDET) of 2.3% on the sale of every device.

The CT scanners and nuclear imaging equipment market segments are expected to show the highest growth among all market segments due to their capability to diagnose large number of diseases effectively in less time. The market for CT scanners was valued at USD 4.35 billion and that for nuclear imaging equipment was value at USD 1.47 billion, in 2012. Both these market segments are expected to show growth at a CAGR of over 5% each.

Geographically, the North American region constituted the largest share by revenue for medical imaging equipment in the year 2012; however, Asia-Pacific is predicted to foresee the highest growth rate of over 7% from 2013 to 2019. This is attributed to rise in geriatric population, and improving healthcare infrastructure in the Asia-Pacific region. In addition, the favorable demand-supply gap for diagnostic services in this region will also propel the growth of this market.

The global medical imaging equipment market is dominated by players such as GE Healthcare, Toshiba America Medical System, Philips Healthcare, Shimadzu Corporation., Siemens Healthcare and Hitachi Medical Corporation. The market is highly oligopolistic in nature with the top three players accounting for about 50% of the global market revenue.

An artificial organ is a man-made device, which is integrated or implanted into the patient, to replace an original diseased organ and restore its specific function. Medical bionics is the study of application of mechanics and electronics to replace a limb or other part of a functional organ that is mechanically powered. With rapid development in healthcare technology, organ transplantation has evolved as a common surgical practice. With years of extensive research and development in the field of medical devices and related technological innovations, artificial vital organs and medical bionics are successfully established as viable alternatives for the replacement of donor organs as the latter are not able to keep pace with an increase in demand for efficient rehabilitation of the physically challenged.

The global artificial vital organs market is segmented into artificial heart, kidney, lungs, liver and pancreas markets. The market for artificial vital organs is led by the artificial kidney segment, in terms of revenue. Increase in prevalence of renal disorders and acute renal failure due to the sedentary lifestyle is a major driver for this market. Increase in the prevalence of cardiovascular diseases leading to acute cardiac failure has led to a growing need for heart replacement. Also, the number of patients awaiting transplant are far more than the availability of donor organs and this has led to an increase in the demand for total artificial heart (TAH). The market for total artificial heart is expected to grow at a CAGR of more than 9% from 2012 to 2018.

The medical bionics market is categorized into ear bionics (cochlear implants), vision bionics, exoskeletons, bionic limbs, brain bionics and cardiac bionics. High prevalence of occupation and age-related disabilities demands novel methods of patient rehabilitation to offer a better life for such patients. The market for exoskeletons is expected to emerge as the fastest growing segment, at a CAGR of over 15% from 2012 to 2018.

Geographically, North America leads the market for artificial vital organs and medical bionics. Aging of the baby boomer population and the corresponding rise in prevalence of acute cases of cardiovascular diseases, renal diseases and respiratory disorders, and the increase in prevalence of age-related disorders and occupation-related disabilities are the major drivers for the growth in demand for artificial organs in North America. However, improvement in healthcare expenditure and healthcare infrastructure and rising scope of medical tourism will increase the market share of Asia-Pacific in the future.

According to a new market report published by Transparency Market Research , "Home Healthcare Market - Global Industry Size, Market Share, Trends, Analysis and Forecast, 2012 - 2018", the global home healthcare market is estimated to be worth USD 195.6 billion in 2012 and is expected to reach the value of USD 305.9 billion by 2018, growing at a CAGR of 7.7% from 2012 to 2018. The Americas region is expected to lead the global home healthcare market in terms of revenue till 2018. The total home healthcare market in the Americas is expected to reach the value of USD 150.8 billion by 2018 followed by Europe with total revenue of USD 80.5 billion.

The rising need to continuously monitor and care for health has increased the global expenditure on healthcare services and products. The trend is also gradually pushing people towards home healthcare products and services, due to their cost efficiency and reliability. This, in turn, is driving the growth of the global home healthcare products and services market. The technological and application developments that have taken place in the home healthcare segment have made them more reliable and globally acceptable. It has also made it feasible for hospitals and patients to get early discharge, and minimize the cost and infrastructure pressures. The growth in certain diseases or medical conditions such as high blood pressure, diabetes, asthma, and other cardiovascular and respiratory diseases, which require continuous monitoring and care, are further driving the home healthcare market growth.

Though the global share of the home healthcare equipment market is considerably less, it is growing at a faster CAGR of 9.9% from 2012 to 2018 due to rising technological innovations, especially in the field of home therapeutic equipment. The home healthcare services market, despite its large share, is expected to grow at a CAGR of 7.4% from 2012 to 2018. The main deterrent, restricting the entry of organized players in this segment is dominance of a large number of small regional players, who are offering their services at low prices, and enjoy high customer loyalty. This has in turn, shifted the attention of big players towards the home healthcare equipment market.

The global market for home healthcare services is classified into respiratory therapy, telemetry, rehabilitation services, infusion therapy, and other unskilled home healthcare services. The unskilled healthcare services are provided by individuals such as family members, unlicensed or traditional caretakers, relatives, and friends. The market for home healthcare services is highly organized in regions such as the Americas and Europe, where it is very efficient. A large share, 79.9%, of the global home healthcare services market is dominated by rehabilitation and unskilled care services. However, the segment is believed to be extremely fragmented, and dominated by small and unorganized players.

This research is specially designed to estimate and analyze the demand and performance of home healthcare equipment and services in a global scenario. The research provides in-depth analysis of home healthcare equipment manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major application segments of the global home healthcare market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered.

Minimally invasive vertebral compression fracture (VCF) repair is one of the fastest growing segments in the overall spinal surgeries market. Factors such as growth in incidence of vertebral compression fractures, high prevalence of osteoporosis, aging of population worldwide and inability of medicinal therapy to cure vertebral compression fracture to the optimum level will have an impact on the growth of the minimally invasive vertebral compression fracture repair industry.

The global minimally invasive vertebral compression fracture repair market is segmented on the basis of types of procedural technology and geography. Based on technology, the minimally invasive VCF repair market is classified into vertebroplasty and kyphoplasty devices. It is expected that the global market for kyphoplasty will reach USD 1.47 billion in 2019 growing at a CAGR of 11.7% from 2013 to 2019.

The United States currently leads the minimally invasive VCF repair market, owing to the early bird advantage rendered by the first launch of innovative products in the country. Growth drivers in the North American minimally invasive VCF repair market include existence of well-defined reimbursement policies, supportive economic base particularly in terms of medical reimbursement, high awareness about VCF conditions and the treatments available. However, countries such as China, Japan, Korea, Australia and India are observed to be potentially emerging markets with higher aging population, development of healthcare infrastructure, high prevalence of osteoporosis and rise in general awareness about healthcare. Countries such as Brazil, Mexico and Argentina are some of the lucrative markets in the Rest of the World.

The global minimally invasive VCF repair market is highly consolidated in nature with companies like Medtronic, Inc. dominating the market with more than 80% of the market share. Some of the other key market players operating in this market include Alphatec Spine, Inc., CareFusion Corporation, Cook Medical, Inc., DFine, Inc., Zimmer Holdings, Globus Medical, Inc. and DePuySynthes, Inc.

Monday, 28 July 2014

According to a new market report published by Transparency Market Research "Orthopedic Devices Market (Hip, Knee, Spine, Shoulder, Elbow, Foot and Ankle, Craniomaxillofacial and Other Extremities) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global orthopedic devices market was valued at USD 29.2 billion in 2012 and is expected to grow at a CAGR of 4.9% from 2013 to 2019, to reach an estimated value of USD 41.2 billion in 2019.

Orthopedic devices are used to provide or restore stability by placing them within the body's skeleton. These help in correcting the problems associated with the bone and joints such as injuries or deformities. Insertion of these orthopedic devices such as joint implants, internal and external fixators involves surgical procedures which can be minimally invasive. Growing elderly population combined with the rise in risk for osteoporosis, osteoarthritis, injuries and obesity, contribute to the growth of this market particularly in emerging economies of the Middle East, and the Asian countries such as China and India.Furthermore, technological advancementssuch asbio-absorbableimplants coupled with increase in the success rate of these implants and fixators in the emerging market, will serve as an opportunity for investors to invest in.

The global market for orthopedic deviceshas been studied from the perspective of widely used various orthopedic devices and number of procedures for particular anatomical location.The report provides a detailed analysis of orthopedic devices for hip, knee, shoulder, elbow, foot and ankle, and other extremities. These are further segmented into joint implants, internal fixation devices and external fixation devices. The others extremities segment comprises the market for wrists, digits and hand. The market has also been estimated for spinal orthopedic devices which includes cervical and thoracolumbar spinal implants and the internal fixation devices. Moreover, orthopedic devices for craniomaxillofacial comprises only of internal fixation devices.

In 2012, knee orthopedic devices accounted for the largest share by revenue of the total orthopedic devices market. However, the product recalls caused dueto factors such as implant loosening, corrosion, wear, and manufacturing errors are expected to have a major impact on the overall marketrevenue. Thus, the U.S. and European markets are anticipated to see a decline in growth during the forecast period.The market for hip orthopedic productsaccounted for the second largest share in 2012. It is estimated that the global market for hip deviceswill grow at a CAGR of over 5.9% from 2013 to 2019, owing to its high incidence rate of hip fractures and demand for hip replacement procedures.

The report also provides market estimations for orthopedic consumables during the forecast period of 2013 to 2019. This market has been segmented as anchors and staples. Anchors form a major share of the total orthopedic consumables market contributing to around 80% of the market share in 2012. The overall orthopedic consumables market is expected to grow to reach a value of USD 457 million by 2019.

Geographically, North America dominatedthe global market for orthopedic devices in terms of revenue generation and is expected to maintain its position throughout the forecast period. The adoption of bio absorbable implants, growing elderly population and rise in incidences of osteoporosis, osteoarthritis, and obesity in the U.S., consequently leading to various types of fractures, is expected to contribute to the leadership of the North American market. Europe was the second largest regional market for orthopedic devicesin 2012, owing to the increased demand for drug eluting stents and infusion pumps. Asia-Pacific is expected to be the fastest growing region in the global orthopedic devices marketfrom 2013 to 2019.

The global hip and knee orthopedic devices market is dominated by major players including Depuy Synthes, Zimmer and Stryker, while the overall spinal devices market is dominated by Medtronic, Depuy, Styrker and NuVasive.

Molecular diagnostics is defined as a class of diagnostic tests that identifies proteins or nucleic acid at a molecular level. This class of test assists in identification of genetic markers of patient or nucleic acids in foreign organism. Currently, molecular diagnostics forms relatively a small portion of the overall diagnostics market but is identified as the fastest growing sector. The growth of this segment is being supported by rapid turnaround time, low cost, convenient workflow and high sensitivity. Moreover, growth of this segment is fuelled by rising incidence of chronic disorders, increasing geriatric population and adoption of personalized medicines. Molecular diagnostics test is rapidly being developed for genetic testing, infectious diseases testing, blood screening, oncology testing, cardiovascular testing and others.

Molecular diagnostics is rapidly an evolving market supported by increasing R&D activities for biomarker identification coupled with emergence of new applications of these tests. Infectious disease alone captures 60% share of the total molecular diagnostics applications market and remaining one third is attributed to genetic testing and blood donor screening. The growth of this segment is driven by rising incidence of cervical cancer caused due to Human Papilloma Virus (HPV). HPV is known to be a causative agent for cervical cancers hence HPV testing is projected to have a CAGR of 14.8% during the forecast period of 2013-2019. Hospital acquired infections (HAI)is anticipated as the fastest growing segment within infectious diseases and is expected to show CAGR of 15.1% from 2013-2019. Oncology testing and HLA typing testing are also projected to grow at a rapid rate during the same forecast period.

Technology wise, PCR accounts for the largest share followed by Transcription Mediated Amplification (TMA), with these two technologies accounting for nearly 50% of the share of molecular diagnostics market. Next generation sequencing is expected to witness the highest growth rate in the near future. High sensitivity, reliability and rapid turnaround time are some of the factors that are expected to trigger market growth. Microarray and hybridization techniques are also expected to show moderate growth. However, issues with reimbursement policies and strict regulatory requirements are some factors, expected to hinder the growth of molecular diagnostics market.

Geographically, North America and Europe comprises majority of the molecular diagnostics market share. Increasing investments in genomics and proteomics, rising awareness and acceptance of personalized medicines along with increasing incidence of chronic diseases are some of the factors that have driven the molecular diagnostics industry in these regions. However, Asia-Pacific is projected to witness fastest growth rate during the forecast period, reporting a CAGR of more than 14%. Economic developments and rising patient awareness towards wellness, preventive medicine and access to technologically advanced products are some of the key growth factors in this region. Additionally, growth in this market is fuelled by spread of infectious diseases such as H1N1, HIV, rise in aging population, and robust government support.

Molecular diagnostics market is highly fragmented comprising small and large vendors. Roche Diagnostics is expected to lead the market owing to its extensive product portfolio in the molecular diagnostics segment. Other players of this market include Novartis Diagnostics, Abbott Laboratories, Qiagen, Hologic Gen-Probe, among others.

Pulmonary drug delivery systems use the respiratory tract to deliver medications to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The history of use of these systems dates back to over 60 years ago, when these systems were initially indicated for treating only respiratory diseases - asthma and COPD. Continued development in this area facilitated their application in the treatment of other diseases as well, including cystic fibrosis and diabetes. Exubera was the first inhalable insulin launched by Pfizer Ltd. and Nektar Pharma for treating diabetes, in 2006. However,owing to its poor sales performance, Exubera was withdrawn from the market within a yearof its launch which led other partnerships such as Alkermes/Eli Lilly and Aradigm/Novo Nordisk to abandon the development process of inhalable insulin therapies. Currently,Afrezza by MannKind Corporation is the only inhalable insulin under review by the U.S. FDA and is likely to be approved for marketing in the U.S. by mid-2014.

The global market for pulmonary drug delivery systems includes metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. Initially, MDIs used chlorofluorocarbons (CFCs) as propellants.Later due to rising environmental concerns and pressure from Montreal Protocol (1987) recommendation to phase out CFCs, manufacturers started using hydrofluoroalkanes (HFAs) that are considered as safe propellants causing negligible threat ofozone depletion.MDIs accounted for the largest share (56.8%) of the total global pulmonary drug delivery systems market in 2012 and this segment is expected to grow at a CAGR relatively lower than that for DPIs and nebulizer market segments. This is primarily because of the environmental concerns related with the use of CFCs, which led to ban on CFC-based inhalers. Although manufacturers have now started using HFAs the fact that HFAs also emit gases causing ozone layer depletion has led manufacturers to shift their focus more towards the development of DPIs. During the forecast period 2013 to 2019, DPIs are expected to witness greater demand than MDIs owing to propellant free nature of these systems. The market for nebulizers has been anticipated as the fastest growing segment of the pulmonary drug delivery systems market mainly due to the technical advances leading to portability of these devices and rising demand for home based care. The global pulmonary drug delivery systems market has also been segmented on the basis of their application in treating various diseases such as asthma, COPD and cystic fibrosis.

Among the four major geographies of the world, North America and Europe accounted for the first and second largest market shares in 2012 of the global pulmonary drug delivery systems market.The market in these regions is characterized by a range of factors such as patent expiry of many blockbuster inhaler brands, increasing prevalence of asthma and COPD, focus on reducing treatment costs, growing environmental concerns and aging population.Asia-Pacific held the third largest share of the global pulmonary drug delivery systems market in 2012. The region being home to more than half of the world's population represents a large pool of patients suffering from respiratory diseases such as asthma and COPD, and thus, represents a high growth potential market for pulmonary drug delivery systems, estimated to grow at a CAGR of 6.6% during the forecast period.Emerging economies of India and China are expected to favor the positive growth of pulmonary drug delivery systems market in the region by contributing to the rise in healthcare expenditure.

Friday, 25 July 2014

According to a new market report published by Transparency Market Research "Minimally Invasive Surgery Market (Surgical Devices, Monitoring & Visualization Devices, and Endoscopy Devices) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,"in 2012, the global minimally invasive surgery market was valued at USD 25.03 billion and is expected to grow at a CAGR of 10.5% during the forecast period 2013 to 2019 to reach a market value of USD 50.60 billion by 2019.

Minimally invasive surgeries (MIS) are performed with minimal incision in the patient's body and ensure the patients with a reduced duration of hospital stay, minimal patient trauma and reduced recovery time. These advantages associated with MIS along with the rising awareness regarding the same, have increased its popularity among patients as well as physicians.The global market for minimally invasive surgeryhas been estimated togrowat the rate of 10.5% during the forecast period 2013 to 2019. This growth is attributed mainly to the increasing incidences of various diseases such as arthritis, cancer and cardiovascular diseases that usually require surgical treatment of the condition. Aging of the global population, especially in the developed countries, will also trigger the growth of this market since elderly people carry a high risk in terms of success of the surgery and MIS would ensure minimal trauma to the already compromised health of the patient. Likewise, introduction of technologically advanced products in the market such as confocal micro endoscopes, narrow band imaging endoscopes and HD cameras for endoscopes, will further propel the growth of this market since these technologies provide better visualization during the surgery.

Minimally invasive surgeries involve three major categories of devices that include surgical devices, monitoring & visualization devices, and endoscopy devices.The market for surgical devices (ablation devices, electrosurgical devices, and medical robotic systems) accounted for the largest share by revenue of the overall MIS market in 2012. This segment is also expected to show the highest growth during the forecast period, at a CAGR of 11.8%. This growth is attributed to their extensive utilization in performing various minimally invasive procedures with maximum accuracy and ease of operation for the physician.

The different types of surgeries that can be performed via minimally invasive technologies include orthopedic, breast, vascular, thoracic, gynecological, bariatric, cardiac, gastrointestinal and urological surgery. Among these, in 2012, the cardiac surgery market accounted for the largest share in terms of revenue due to the large patient population suffering from cardiovascular diseases (CVDs) globally and the ever-increasing incidence rates of CVDs. However, the market for cosmetic surgery will grow at the highest CAGR of 14% during the forecast period 2013 to 2019. This is due to the change in lifestyle of the population along with high adoption rates for these procedures in developed as well as developing markets.

The North American region accounted for the largest share by revenue of the global minimally invasive surgery market in the year 2012, owing to the large number of elderly people, a well-established reimbursement scenario and presence of leading device manufacturers in the region. However, Asia-Pacific is expected to show the highest growth rate of 13.3% from 2013 to 2019. This is attributed to the rise in disposable income due to economic development in key markets such as India and China, and high adoption rates in the developed market of Japan. Similarly, in the constantly increasing patient pool, aging population and rising healthcare expenditures will also augment the growth of the market. The European and RoW markets are expected to show the slowest growth during the forecast period, although the European market is expected to maintain its position with the second largest revenue share in 2019.

The global minimally invasive surgery market is dominated by players such asIntuitive Surgical, Inc., GE Healthcare, Siemens Healthcare, Philips Healthcare, Medtronic, Inc., Stryker Corporation and Biomet, Inc.These companies together accounted for the largest share in terms of revenue in 2012, at over 45%. Some other key players in the market include Abbott Laboratories, DePuy Synthes, Inc., ArthroCare Corporation, Given Imaging Ltd., NuVasive, Inc., Teleflex, Inc. and Varian Medical Systems, Inc.

According to a new market report published by Transparency Market Research "Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019,"the market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.

The advent of new applications and technology in the field of nanomedicine will be one of the major growth factors for the global nanomedicine market. In addition, increase of funding aimed at boosting the research activities pertaining to nanomedicine by the government as well as private institutions will expedite the process of commercialization of new products and hence will drive the market. Other driving factors include rising base of geriatric population, presence of high unmet medical needs and rising worldwide incidences of chronic diseases.

The global nanomedicine market by applications was dominated by the oncology market with a market share of approximately 38.0% in 2012 on account of the presence of high number of commercialized products in this segment. Development of nanomedicine products enabling drugs crossing blood brain barrier and targeting the tumor in brain and at other sites in the body will prove to be a significant future growth driver for this market.

However, the global cardiovascular market for nanomedicine is the fastest growing application segment. Factors such as the presence of large patient prevalence coupled with rising demand for nanotechnology enabled drugs and devices catering to this segment, attribute to its high growth rate.

North America dominated the market in 2012 and is expected to maintain its market position till 2019. However, theAsia-Pacific market is estimated to grow at a faster pace (CAGR of 14.6% from 2013 to 2019).Europe is expected to grow at a relatively higher rate compared to North America owing to constantly improving regulatory framework and the presence of an extensive product pipeline portfolio.